{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:4245"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:4245","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Validation and identification of tumour endothelial markers and their uses in cancer vaccine","abstract":"The abnormal tumour microenvironment, which is typically hypoxic, acidic and with poor blood flow, induces the endothelial expression of genes not found on normal microvessels. By selectively targeting these tumour endothelial markers (TEMs) it is possible to induce tumour regression, presenting a potential strategy for therapeutic intervention. Potential TEMs were predicted by bioinformatics data mining. Validation of these TEM candidates identified a novel TEM CLEC14A. Functional characterization suggests a regulatory role of CLEC14A in endothelial cell migration. Inhibition of endothelial migration by CLEC14A antisera or monoclonal antibody holds therapeutic promise for the treatment of cancer. Differential gene expression analysis of freshly isolated lung tumour endothelium by 2nd generation sequencing identified 13 putative TEMs. Subsequent validation work confirmed six of which to be expressed on lung tumour vasculature. Finally, a pre-validated marker, Robo4, was investigated as a cancer vaccine. A strong antibody response was induced by delivery of pure mouse Robo4 protein or a Robo4 conjugate. The in vivo sponge assay in Robo4 vaccinated mice showed a significant reduction in vessel invasion. Tumour implantation experiments in vaccinated mice showed a marked delay in tumour growth.","abstract_html":"The abnormal tumour microenvironment, which is typically hypoxic, acidic and with poor blood flow, induces the endothelial expression of genes not found on normal microvessels. By selectively targeting these tumour endothelial markers (TEMs) it is possible to induce tumour regression, presenting a potential strategy for therapeutic intervention. Potential TEMs were predicted by bioinformatics data mining. Validation of these TEM candidates identified a novel TEM CLEC14A. Functional characterization suggests a regulatory role of CLEC14A in endothelial cell migration. Inhibition of endothelial migration by CLEC14A antisera or monoclonal antibody holds therapeutic promise for the treatment of cancer. Differential gene expression analysis of freshly isolated lung tumour endothelium by 2nd generation sequencing identified 13 putative TEMs. Subsequent validation work confirmed six of which to be expressed on lung tumour vasculature. Finally, a pre-validated marker, Robo4, was investigated as a cancer vaccine. A strong antibody response was induced by delivery of pure mouse Robo4 protein or a Robo4 conjugate. The in vivo sponge assay in Robo4 vaccinated mice showed a significant reduction in vessel invasion. Tumour implantation experiments in vaccinated mice showed a marked delay in tumour growth.","abstract_has_math":false,"creators":["Zhuang, Xiaodong"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-07","date_published":"2013-07","updated_at":"2026-11-19T09:27:36Z","subjects":["QR180 Immunology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/4245/1/Zhuang13PhD%5B1%5D.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A4245","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["cancer_research_uk","other"]},{"key":"dc:creator","label":"Author","values":["Zhuang, Xiaodong"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013-07"]},{"key":"dc:date.issued","label":"Date","values":["2013-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Immunity and Infection"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/4245/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QR180 Immunology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/4245/1/Zhuang13PhD%5B1%5D.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The abnormal tumour microenvironment, which is typically hypoxic, acidic and with poor blood flow, induces the endothelial expression of genes not found on normal microvessels. By selectively targeting these tumour endothelial markers (TEMs) it is possible to induce tumour regression, presenting a potential strategy for therapeutic intervention. Potential TEMs were predicted by bioinformatics data mining. Validation of these TEM candidates identified a novel TEM CLEC14A. Functional characterization suggests a regulatory role of CLEC14A in endothelial cell migration. Inhibition of endothelial migration by CLEC14A antisera or monoclonal antibody holds therapeutic promise for the treatment of cancer. Differential gene expression analysis of freshly isolated lung tumour endothelium by 2nd generation sequencing identified 13 putative TEMs. Subsequent validation work confirmed six of which to be expressed on lung tumour vasculature. Finally, a pre-validated marker, Robo4, was investigated as a cancer vaccine. A strong antibody response was induced by delivery of pure mouse Robo4 protein or a Robo4 conjugate. The in vivo sponge assay in Robo4 vaccinated mice showed a significant reduction in vessel invasion. Tumour implantation experiments in vaccinated mice showed a marked delay in tumour growth."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Validation and identification of tumour endothelial markers and their uses in cancer vaccine"]}]}],"canonical_facts":{"dc:contributor.sponsor":["cancer_research_uk","other"],"dc:creator":["Zhuang, Xiaodong"],"dc:date":["2013-07"],"dc:date.issued":["2013-07"],"dc:description.abstract":["The abnormal tumour microenvironment, which is typically hypoxic, acidic and with poor blood flow, induces the endothelial expression of genes not found on normal microvessels. By selectively targeting these tumour endothelial markers (TEMs) it is possible to induce tumour regression, presenting a potential strategy for therapeutic intervention. Potential TEMs were predicted by bioinformatics data mining. Validation of these TEM candidates identified a novel TEM CLEC14A. Functional characterization suggests a regulatory role of CLEC14A in endothelial cell migration. Inhibition of endothelial migration by CLEC14A antisera or monoclonal antibody holds therapeutic promise for the treatment of cancer. Differential gene expression analysis of freshly isolated lung tumour endothelium by 2nd generation sequencing identified 13 putative TEMs. Subsequent validation work confirmed six of which to be expressed on lung tumour vasculature. Finally, a pre-validated marker, Robo4, was investigated as a cancer vaccine. A strong antibody response was induced by delivery of pure mouse Robo4 protein or a Robo4 conjugate. The in vivo sponge assay in Robo4 vaccinated mice showed a significant reduction in vessel invasion. Tumour implantation experiments in vaccinated mice showed a marked delay in tumour growth."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/4245/1/Zhuang13PhD%5B1%5D.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Immunity and Infection"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/4245/"],"dc:subject":["QR180 Immunology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public"],"dc:title":["Validation and identification of tumour endothelial markers and their uses in cancer vaccine"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:27:36Z"}